Aprea Therapeutics (NASDAQ: APRE)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.380 | -0.360 | 0.0200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Aprea Therapeutics (NASDAQ: APRE) through any online brokerage.
Other companies in Aprea Therapeutics’s space includes: Geovax Labs (NASDAQ:GOVX), TransCode Therapeutics (NASDAQ:RNAZ), Indaptus Therapeutics (NASDAQ:INDP), CohBar (NASDAQ:CWBR) and RenovoRx (NASDAQ:RNXT).
The latest price target for Aprea Therapeutics (NASDAQ: APRE) was reported by HC Wainwright & Co. on Wednesday, March 16, 2022. The analyst firm set a price target for 2.00 expecting APRE to rise to within 12 months (a possible 149.88% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Aprea Therapeutics (NASDAQ: APRE) is $0.8004 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Aprea Therapeutics.
Aprea Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Aprea Therapeutics.
Aprea Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.